NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT) Is Down 11.9% After MRD-Led Earnings Beat And Tax-Driven Insider Sales - Has The Bull Case Changed?
In March 2026, Adaptive Biotechnologies reported fourth-quarter 2025 results that beat analyst expectations, with revenue growth led by its Minimal Residual Disease (MRD) business, while several senior executives sold shares largely to cover tax obligations linked to vested equity awards.
This combination of stronger MRD performance and insider sales tied mainly to tax withholding offers insight into how operational momentum and routine executive transactions can coexist without necessarily...